Results 101 to 110 of about 11,499 (250)

Effectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus: Real-World Evidence in Indian Patients [NOVELTY Study]

Drugs - Real World Outcomes
Background and Objective Vildagliptin sustained release (XR), a formulation that provides vildagliptin 100 mg with a once-daily dose administration, is a recent introduction to manage type 2 diabetes mellitus in India.
Rakesh Sahay, Anil Bhansali, Surendra Kumar Sharma, Rahul Iyer, Amarnath Sugumaran, Senthilnathan Mohanasundaram, Jaideep Gogtay   +6 more
doaj   +1 more source

Bullous pemphigoid induced by the dipeptidyl-peptidase IV inhibitors (gliptins) [PDF]

, 2014
Background Bullous pemphigoid (BP) is the most frequent autoimmune blistering dermatosis. Recently, the development of BP in patients treated with gliptins, also known as DPP-4 inhibitors, alone or in association with metformin has been outlined in case ...
SCHAFFER, C.
core  

Bioequivalence Study of Fixed-Dose Combination of Remogliflozin Etabonate 100 mg/Vildagliptin 50 mg with Individual Components in Healthy Indian Male Subjects under Fed Conditions [PDF]

, 2022
Shashank Joshi
openalex   +1 more source

Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

BMC Pharmacology and Toxicology, 2017
Background Vildagliptin and pioglitazone/rosiglitazone are emerging Oral Hypoglycemic Agents (OHAs) which are used to treat patients suffering from Type 2 Diabetes Mellitus (T2DM).
Pravesh Kumar Bundhun, Girish Janoo, Abhishek Rishikesh Teeluck, Feng Huang   +3 more
doaj   +1 more source

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

Drug Design, Development and Therapy, 2014
Mustafa Cakirca,1 Cumali Karatoprak,1 Mehmet Zorlu,1 Muharrem Kiskac,1 Mustafa Kanat,2 Mehmet Ali Cikrikcioglu,1 Pinar Soysal,3 Mehmet Hursitoglu,4 Ahmet Adil Camli,1 Reha Erkoc,1 Muhammad Abdul-Ghani5 1Internal Medicine Clinic, Faculty of Medicine ...
Cakirca M, Karatoprak C, Zorlu M, Kiskac M, Kanat M, Cikrikcioglu MA, Soysal P, Hursitoglu M, Camli AA, Erkoc R, Abdul-Ghani M   +10 more
doaj  

Molecular cloning and biochemical characterization of Xaa-Pro dipeptidyl-peptidase from Streptococcus mutans and its inhibition by anti-human DPP IV drugs

, 2016
Streptococcus mutans harbours an intracellular, human DPP IV-analogous enzyme Xaa-Pro dipeptidyl-peptidase (EC 3.4.14.11). According to previous reports, an extracellular isozyme in S. gordonii and S. suis has been associated with virulence.
De, A, Lupidi, Giulio, Petrelli, Dezemona, Vitali, Luca Agostino   +3 more
core   +1 more source

Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice [PDF]

, 2007
Grace Flock, Laurie L. Baggio, Christine Longuet, Daniel J. Drucker   +3 more
openalex   +1 more source

Two Cases of Bullous Pemphigoid Induced by Vildagliptin [PDF]

, 2018
Aslı ÜNAL DOĞRUK, Özlem Tarçın, Gülşen Tukenmez Demırcı, Ebru DEMİRALAY, A.Tülin Mansur, Şemsi YILMAZ, Nilgün Güvener Demirağ   +6 more
openalex   +1 more source

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study

Diabetes, Metabolic Syndrome and Obesity, 2016
Ahmed AK Hassoun,1 Md Faruque Pathan,2 Rita C Medlej,3,4 Monira Alarouj,5 Inass Shaltout,6 Manoj S Chawla,7 Ditte Knap,8 Julius A Vaz9 1Dubai Diabetes Centre, Dubai, UAE; 2Department of Endocrinology, BIRDEM Hospital, Dhaka, Bangladesh; 3Department of ...
Hassoun AAK, Pathan MF, Medlej RC, Alarouj M, Shaltout I, Chawla MS, Knap D, Vaz JA   +7 more
doaj  

Comparative Effectiveness and Safety of Acarbose and Vildagliptin in Type 2 Diabetes Management: A Real-World Observational Study in an Indian Population

Clinical Diabetology
OBJECTIVE: To evaluate and compare the real-world effectiveness and safety profiles of Acarbose and Vildagliptin in patients with type 2 diabetes (T2D), with an additional focus on their impacts on the gut microbiota.
Shambo Samrat Samajdar, Shatavisa Mukherjee, Rutul Gokalani, Supratik Bhattacharyya, Banshi Saboo, Shashank Joshi   +5 more
doaj   +1 more source